More Resverlogix Corp. news Resverlogix Corp.TSX: RVX Resverlogix Commences Phase 3 Clinical Trial BETonMACE With Apabetalone Oct 26, 2015 at 7:00 AM EDT · Issued by Resverlogix Corp. via CNW On 6ix: 6ix.com/news/resverlogix-commences-phase-3-clinical-trial-betonmace-with-apabetaloneCopyright CNW Group 2015 View original source (CNW)Resverlogix Corp. on 6ix Story so farResverlogix Presents New Data at the European Society of Cardiology Congress 2015 on RVX-208 'apabetalone' a Selective BET InhibitorAug 31, 2015International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"Aug 4, 2015 Earlier from ResverlogixResverlogix Corp. Selected to Present at Cavendish Global Health Impact ForumOct 22, 2015Resverlogix Announces Voting ResultsSep 30, 2015Resverlogix Provides Research and Development Update in New York CitySep 29, 2015Resverlogix Announces the commencement of an Orphan Disease Program specific for Complement Mediated DiseasesSep 24, 2015Resverlogix Presents at the Rodman & Renshaw 17th Annual Global Investment ConferenceSep 10, 2015Later from ResverlogixResverlogix Presents Important New Data at the Annual American Society of Nephrology Kidney Week ConferenceNov 9, 2015Resverlogix Commences Dosing in Phase 3 Clinical Trial BETonMACENov 11, 2015Resverlogix's Manuscript on BET-inhibitor apabetalone (RVX-208) Accepted into the Atherosclerosis JournalJan 25, 2016Resverlogix Further Strengthens the Board of Directors and Appoints a New ChairmanApr 4, 2016The New York Academy of Sciences Collaborates with Resverlogix to Host Epigenetics SymposiumApr 18, 2016All Resverlogix news releases↗Follow Resverlogix into a list and get an email when it puts out news.Follow Resverlogix